Still's Disease, Adult-Onset
10
3
4
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
10.0%
1 terminated out of 10 trials
83.3%
-3.2% vs benchmark
20%
2 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
Assessment of Macrophage Activation syndromE in STill's Disease in Italy
Glycosylated Ferritin in Macrophagic Activation Syndromes
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
Assessment of Macrophage Activation syndromE in STill's Disease
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)
Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease
Interleukin-1 Trap to Treat Autoinflammatory Diseases